Response Genetics' Q1 Revenues Jump 140 Percent | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Response Genetics this week reported first-quarter 2010 revenue growth of 140 percent, driven by its Response DX test sales.

The Los Angeles, Calif.-based molecular diagnostics firm had total revenues of $3.7 million for the three-month period ended March 31, compared to $1.5 million for the first quarter of 2009. It said that sales of its Response DX genetic tests rose to $1.72 million from $263,000 for the first quarter of 2009.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nature this week: genome-wide transcriptome analysis of brain samples from people with autism spectrum disorder, flounder genome, and more.

Researchers used T-cell transfer therapy to target mutation KRAS, according to the New York Times.

The US Senate has passed the 21st Century Cures Act, which would provide a funding boost at NIH while overhauling FDA policies.

Bloomberg reports that President-elect Donald Trump is considering Jim O'Neill for Food and Drug Administration commissioner.